Top

Published in:

10-04-2024 | Lymphoma | Rapid Short communication

Recent advances in liquid biopsy of central nervous system lymphomas: case presentations and review of the literature

Authors: Manabu Natsumeda, Satoshi Shibuma, Haruhiko Takahashi, Jotaro On, Yoshihiro Mouri, Kaoru Tomikawa, Hidemoto Fujiwara, Jun Watanabe, Yoshihiro Tsukamoto, Masayasu Okada, Rui Takeda, Hiroshi Shimizu, Jun Takizawa, Akiyoshi Kakita, Makoto Oishi

Published in: Brain Tumor Pathology | Issue 2/2024

Abstract

Surgical biopsy is the gold standard for diagnosing central nervous system (CNS) lymphomas. However, reliable liquid biopsy methods for diagnosing CNS lymphomas have quickly developed and have been implicated in clinical decision-making. In the current report, we introduce two patients for whom liquid biopsy was essential for diagnosing CNS lymphomas and discuss the rapidly growing applications of this technology.

Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, Tanaka K, Fukushima S, Takami H, Arita H et al (2016) Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol 42:279–290PubMedCrossRef

Yamaguchi J, Ohka F, Lushun C, Motomura K, Aoki K, Takeuchi K, Nagata Y, Ito S, Mizutani N, Ohno M et al (2023) CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma. Cancer Med 12:7116–7126PubMedCrossRef

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679–690PubMedCrossRefPubMedCentral

Raja H, Salomão DR, Viswanatha DS, Pulido JS (2016) Prevalence of MYD88 L265P mutation in histologically proven, diffuse large B-cell vitreoretinal lymphoma. Retina 36:624–628PubMedCrossRef

Bonzheim I, Giese S, Deuter C, Süsskind D, Zierhut M, Waizel M, Szurman P, Federmann B, Schmidt J, Quintanilla-Martinez L et al (2015) High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood 126:76–79PubMedCrossRef

Yonese I, Takase H, Yoshimori M, Onozawa E, Tsuzura A, Miki T, Mochizuki M, Miura O, Arai A (2019) CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential. Eur J Haematol 102:191–196PubMedCrossRef

Watanabe J, Natsumeda M, Okada M, Kobayashi D, Kanemaru Y, Tsukamoto Y, Oishi M, Kakita A, Fujii Y (2019) High detection rate of MYD88 mutations in cerebrospinal fluid from patients with central nervous system lymphomas. JCO Precis Oncol 3:1–13PubMedCrossRef

Watanabe J, Natsumeda M, Kanemaru Y, Okada M, Oishi M, Kakita A, Fujii Y (2019) Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma. Leuk Lymphoma 60:3587–3589PubMedCrossRef

Baraniskin A, Schroers R (2021) Liquid biopsy and other non-invasive diagnostic measures in PCNSL. Cancers 13:2665PubMedCrossRefPubMedCentral

10.

Morell AA, Shah AA-O, Cavallo C, Eichberg DG, Sarkiss CA, Benveniste R, Ivan ME, Komotar RJ (2019) Diagnosis of primary central nervous system lymphoma: a systematic review of the utility of csf screening and the role of early brain biopsy. Neurooncol Pract 6:415–423PubMedPubMedCentral

11.

On J, Natsumeda M, Watanabe J, Saito S, Kanemaru Y, Abe H, Tsukamoto Y, Okada M, Oishi M, Yoshimura J et al (2021) Low detection rate of h3k27m mutations in cerebrospinal fluid obtained from lumbar puncture in newly diagnosed diffuse midline gliomas. Diagnostics (Basel) 11:681PubMedCrossRef

12.

Natsumeda M, On J, Watanabe J, Takahashi H, Tsukamoto Y, Okada M, Hiraishi T, Yoshimura J, Oishi M, Fujii Y (2022) Characteristics of diffuse mildline gliomas with positive detection of H3K27M mutations in cerebrospinal fluid. Nerv Syst Child 44:358–364

13.

Natsumeda M, On J, Watanabe J, Tsukamoto Y, Okada M, Fujii Y, Adachi J, Nishikawa R (2021) The present and future of less-invasive liquid biopsy for the diagnosis of gliomas and brain tumors. No Shinkei Geka 49:527–534PubMed

14.

Mutter JA, Alig SK, Esfahani MS, Lauer EM, Mitschke J, Kurtz DM, Kuhn J, Bleul S, Olsen M, Liu CL et al (2023) Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas. J Clin Oncol 41:1684–1694PubMedCrossRef

15.

Takahashi H, Natsumeda M, On J, Watanabe J, Tada M, Shimizu H, Tsukamoto Y, Okada M, Oishi M, Takizawa J et al (2023) Administration of glucocorticoids prior to liquid biopsy dramatically reduces the detection rate of MYD88 L265P mutation in cerebrospinal fluid of primary CNS lymphoma patients. Leuk Lymphoma 64:1219–1222PubMedCrossRef

16.

Yamagishi Y, Sasaki N, Nakano Y, Matushita Y, Omura T, Shimizu S, Saito K, Kobayashi K, Narita Y, Kondo A et al (2021) Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma. Cancer Sci 112:4702–4710PubMedCrossRefPubMedCentral

17.

Hiemcke-Jiwa LS, Minnema MC, Radersma-van Loon JH, Jiwa NM, de Boer M, Leguit RJ, de Weger RA, Huibers MMH (2018) The use of droplet digital PCR in liquid biopsies: a highly sensitive technique for MYD88 p. (L265P) detection in cerebrospinal fluid. Hematol Oncol 36:429–435PubMedCrossRef

18.

Rimelen V, Ahle G, Pencreach E, Zinniger N, Debliquis A, Zalmai L, Harzallah I, Hurstel R, Alamome I, Lamy F et al (2019) Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis. Acta Neuropathol Commun 7:43PubMedCrossRefPubMedCentral

19.

Heger J-M, Mattlener J, Schneider J, Gödel P, Sieg N, Ullrich F, Lewis RI, Bucaciuc-Mracica T, Schwarz RF, Rueß D et al (2023) Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA. Blood 143:522–534CrossRef

20.

Zheng X, Li P, Dong Q, Duan Y, Yang S, Cai Z, Chen F, Li W (2021) MicroRNAs as diagnostic biomarkers in primary central nervous system lymphoma: a systematic review and meta-analysis. Front Oncol 11:743542PubMedCrossRefPubMedCentral

21.

Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985–990PubMedCrossRef

22.

Gonzolez-Aguilar A, Ibdaih A, Boisselier B, Habbita N, Rosetto M, Laurenge A, Bruno A, Jouvet A, Polivka M, Adam C et al (2012) Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 18:5203–5211CrossRef

23.

Bruno A, Boisselier B, Labreche K, Marie Y, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Eimer S et al (2014) Mutational analysis of primary central nervous system lymphoma. Oncotarget 5:5065–5075PubMedCrossRefPubMedCentral

24.

Braggio E, Van Wier S, Ojha J, McPhail E, Asmann YW, Egan J, da Silva JA, Schiff D, Lopes MB, Decker PA et al (2015) Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res 21:3986–3994PubMedCrossRefPubMedCentral

25.

Yamada S, Ishida Y, Masuno A, Yamazaki K (2015) Primary diffuse large b-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leuk Lymphoma 56:2141–2145PubMedCrossRef

26.

Hattori K, Sakata-Yanagimoto M, Okoshi Y, Goshima Y, Yanagimoto S, Nakamoto-Matsubara R, Sato T, Noguchi M, Takano S, Ishikawa E et al (2016) MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma. Br J Haematol 177:481–497

27.

Nayyar N, White MD, Gill CM, Lastrapes M, Bertalan M, Kaplan A, D’Andrea MR, Bihun I, Kaneb A, Dietrich J et al (2019) MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Adv 3:375–383PubMedCrossRefPubMedCentral

28.

Bravetti C, Degaud M, Armand M, Sourdeau E, Mokhtari K, Maloum K, Osman J, Verrier P, Houillier C, Roos-Weil D et al (2023) Combining MYD88 L265P mutation detection and clonality determination on CSF cellular and cell-free DNA improves diagnosis of primary CNS lymphoma. Br J Haematol 201:1088–1096PubMedCrossRef

29.

Ferreri AJM, Calimeri T, Lopodote P, Francaviglia I, Daverio R, Iacona C, Belloni C, Steffanoni S, Gulino A, Anghileri E et al (2021) MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. Br J Haematol 193:497–505PubMedCrossRef

30.

Sasayama T, Nakamizo S, Nishihara M, Kawamura A, Tanaka H, Mizukawa K, Miyake S, Taniguchi M, Hosoda K, Kohmura E (2012) Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro Oncol 14:368–380PubMedCrossRef

31.

Gupta M, Burns EJ, Georgantas NZ, Theirauf J, Nayyar N, Gordon A, Jones SS, Pisapia M, Sun Y, Burns RP et al (2021) A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood 138:382–386PubMedCrossRefPubMedCentral

32.

Hayashi T, Tateishi K, Matsuyama S, Iwashita H, Miyake Y, Oshima A, Honma H, Sasame J, Takabayashi K, Sugino K et al (2023) Intraoperative integrated diagnostic system for malignant central nervous system tumors. Clin Cancer Res 30:116–126CrossRef

33.

Haider Z, Wasterlid T, Spangberg LD, Rabbani L, Jylha C, Thorvaldsdottir B, Skaftason A, Awier HN, Krstic A, Gellerbring A et al (2023) Whole-genome informed circulating tumor DNA analysis by multiplex digital pcr for disease monitoring in B-cell lymphomas: a proof-of-concept study. Front Oncol 13:1176698PubMedCrossRefPubMedCentral

34.

Yamaguchi J, Ohka F, Kitano Y, Maeda S, Motomura K, Aoki K, Takeuchi K, Nagata Y, Hattori H, Tsujiuchi T et al (2023) Rapid detection of the MYD88 L265P mutation for pre- and intra-operative diagnosis of primary central nervous system lymphoma. Cancer Sci 114:2544–2551PubMedCrossRefPubMedCentral

35.

Yu X, Li W, Deng Q, Li L, Hsi ED, Young KH, Zhang M, Li Y (2018) MYD88 L265P mutation in lymphoid malignancies. Cancer Res 78:2457–2462PubMedCrossRef

36.

Fernando MR, Chen K, Norton S, Krzyzanowski G, Bourne D, Hunsley B, Ryan WL, Bassett C (2010) A new methodology to preserve the original proportion and integrity of cell-free fetal DNA in maternal plasma during sample processing and storage. Prenat Diagn 30:418–424PubMedCrossRef

37.

Alidousty C, Brandes D, Heydt C, Wagener S, Wittersheim M, Schafer SC, Holz B, Merkelbach-Bruse S, Buttner R, Fassunke J, Schultheis AM (2017) Comparison of blood collection tubes from three different manufacturers for the collection of cell-free DNA for liquid biopsy mutation testing. J Mol Diag 19:801–804CrossRef

38.

Rajyaguru DJ, Bhaskar C, Borgert AJ, Smith A, Parsons B (2016) Intravascular large B cell lymphoma in the United States (US): a population- based study using surveillance, epidemiology, and end results program and national cancer data base. Blood 128:1114CrossRef

39.

Ferreri AJM, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, Zucca E, Rossi G, López-Guillermo A, Pavlovsky MA et al (2004) Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant.’ Br J Haematol 127:173–183PubMedCrossRef

40.

Hirami Y, Nishimura MF, Urata T, Morimoto M, Maekawa Y, Yoshino T, Nishimura Y, Sato Y (2022) Comparison of serum sIL-2R and LDH levels in patients with intravascular large B-cell lymphoma and patients with advanced stage diffuse large B-cell lymphoma. J Clin Exp Hematop 63:25–31CrossRef

41.

Kitahara S, Kanazawa M, Natsumeda M, Sato A, Ishikawa M, Hara K, Tabe H, Makino K, Okamoto K, Fujita N et al (2023) Progressive conus medullaris lesions are suggestive of intravascular large B-cell lymphoma. Eur J Neurol 30:3236–3243PubMedCrossRef

42.

Matsue K, Abe Y, Kitadate A, Miura D, Narita K, Kobayashi H, Takeuchi M, Enzan N, Tanaka A, Takeuchi K (2019) Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Blood 133:1257–1259PubMedCrossRefPubMedCentral

43.

Matsue K, Asada N, Odawara J, Aoki T, Kimura S, Iwama K, Fujiwara H, Yamakura M, Takeuchi M (2011) Random skin biopsy and bone marrow biopsy for diagnosis of intravascular large B cell lymphoma. Ann Hematol 90:417–421PubMedCrossRef

44.

Shimada K, Yoshida K, Suzuki Y, Iriyama C, Inoue Y, Sanada M, Kataoka K, Yuge M, Takagi Y, Kusumoto S et al (2021) Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma. Blood 137:1491–1502PubMedCrossRefPubMedCentral

45.

Meriranta L, Alkodsi A, Pasanen A, Lepistö M, Mapar P, Blaker YN, Jørgensen J, Karjalainen-Lindsberg M-L, Fiskvik I, Mikalsen LTG et al (2022) Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood 139:1863–1877PubMedCrossRef

46.

Tateishi K, Miyake Y, Kawazu M, Sasaki N, Nakamura T, Sasame J, Yoshii Y, Ueno T, Miyake A, Watanabe J et al (2020) A hyperactive rela/p65-hexokinase 2 signaling axis drives primary central nervous system lymphoma. Cancer Res 80:5330–5343PubMedCrossRef

Title: Recent advances in liquid biopsy of central nervous system lymphomas: case presentations and review of the literature
Authors: Manabu Natsumeda
Satoshi Shibuma
Haruhiko Takahashi
Jotaro On
Yoshihiro Mouri
Kaoru Tomikawa
Hidemoto Fujiwara
Jun Watanabe
Yoshihiro Tsukamoto
Masayasu Okada
Rui Takeda
Hiroshi Shimizu
Jun Takizawa
Akiyoshi Kakita
Makoto Oishi
Publication date: 10-04-2024
Publisher: Springer Nature Singapore
Keyword: Lymphoma
Published in: Brain Tumor Pathology / Issue 2/2024
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI: https://doi.org/10.1007/s10014-024-00483-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Recent advances in liquid biopsy of central nervous system lymphomas: case presentations and review of the literature

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2024

Correction: Beyond the WHO 2021 classification of the tumors of the central nervous system: transitioning from the 5th edition to the next

Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for gliomas

Rise of oligodendroglioma hypermutator phenotype from a subclone harboring TP53 mutation after TMZ treatment

Clinical and radiological features of intracranial ancient schwannomas: a single-institution, retrospective analysis

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy

Preface for Brain Tumor Pathology vol.41 issue 2